Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab* (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-Line Platinum-Containing Chemotherapy

Status
Closed
Cancer Type
Bladder Cancer
Kidney Cancer
Trial Phase
Phase III
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT02603432
Protocol IDs
B9991001 (primary)
NCI-2016-00304
2015-003262-86
JAVELIN Bladder 100
Study Sponsor
Pfizer

Summary

The main purpose of this study is to compare maintenance treatment with avelumab plus best

supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in

patients with locally advanced or metastatic urothelial cancer that did not worsen during or

following completion of first-line chemotherapy.

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.